Frontier Pharma: Transplantation
Therapeutics-A Highly Innovative Pipeline with a Range of Adaptive and
Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and
Kidney Transplantation
In 2015 a total of 127,000 transplantations were performed
worldwide, an increase of 5.8% from 2014, with 33,000 of these occurring in the
EU and 32,000 in the US. Approximately 60% of these were kidney transplants,
with liver, heart, lung, pancreas and small bowel transplantations accounting
for the other most common procedures (Dominguez-Gil and Matesanz, 2017). When a
graft is transplanted from a genetically non-identical individual, the recipient’s
immune system recognizes the graft as foreign.
This leads to an anti-graft immune response that involves T
cells invading the new tissue, multiplying, and recruiting more immune cells to
the transplant site in order to remove this foreign body. Depending on the
nature of the incompatibility and the immune response, and acute or chronic
rejection process can occur. Conversely, if the graft consists of hematopoietic
stem cells or immune cells, there is a risk that they will mount an immune
response against the host, known as graft versus host disease (GVHD). There are
several safe pharmacological treatment options for acute rejections, but
long-term treatment options remain unsatisfactory.
The risk of infection limits the effectiveness of these
therapies, and improvements to their efficacy are also needed. Specific
transplantation tolerance, in which alloreactive T cells are inactivated while
the broader immune response is left intact, removing the need for broad
immunosuppressant therapies, can be considered to be the ultimate goal for
clinical transplantation. Compared with the overall immunology pipeline, in
which there are 1,915 products, the transplantation pipeline is small, with
only 244 products. However, of the 145 products in the transplantation pipeline
with a disclosed molecular target, there are 65 first-in-class products, acting
on a total of 63 distinct first-in-class targets, highlighting the fact that
this pipeline displays strong levels of innovation.
There is a need for therapies that can achieve
graft-specific immunosuppression, without having a general effect on the wider
immune system. Which therapies and technologies currently in development are
most likely to achieve this? There are 63 distinct first-in-class molecular
targets in development for transplantation. Which of these hold the strongest
potential in the clinic, and which are closest to reaching the market? How
effective are current therapies for these indications, and how have they been
able to improve the general prognosis in recent decades? Which molecule types
and molecular targets are most prominent across transplantation therapy? Which
specific types of transplantation are being most heavily studied across the
pharmaceutical pipeline?
Appreciate the current clinical and commercial landscapes by
considering disease symptoms, pathogenesis, etiology, co-morbidities and
complications, epidemiology, diagnosis, prognosis and treatment options for
transplantation rejection. Identify leading products and key unmet needs within
the market. Recognize trends in pipeline innovation by analyzing therapies by
stage of development, molecule type and molecular target. Assess the
therapeutic potential of first-in-class targets. Using a proprietary molecular
target matrix assessment, first-in-class targets in the pipeline have been
assessed and ranked according to clinical potential. Consider first-in-class
pipeline products with no prior involvement in licensing and co-development
deals, which may represent potential investment opportunities.
Key topics covered in the Report:-
Transplantation therapeutics Global Market Research Report
Transplantation therapeutics Global Market Size
Transplantation therapeutics Global Report
Transplantation therapeutics Global Market
Transplantation therapeutics Global Analysis
Transplantation therapeutics Global Market Forecast
Transplantation therapeutics Global Market Major Players
Transplantation therapeutics Global Market Forecast
Transplantation therapeutics Global Market Analysis
Transplantation therapeutics Global Leading Competitors
To know more, click on the link below:
Related Reports:-
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
sales@kenresearch.com
0124-4230204
